Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-17
2006-01-17
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S274700, C544S242000, C544S297000
Reexamination Certificate
active
06987119
ABSTRACT:
Compounds of formula (I):wherein X is O, CH2, S or NH, or the moiety X—R1is hydrogen;V is CH or N;R1is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclyl-C1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except hydrogen may be optionally substituted;R2and R3independently represent hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heteroaryl, heteroarylC1-6alkyl, heterocyclyl, or heterocyclylC1-6alkyl any one of which except hydrogen may be optionally substituted, or R2and R3together with the nitrogen atom to which they are attached form a 4- to 10-membered optionally substituted monocyclic or bicyclic ring;Ar is an aryl or heteroaryl ring either of which may be optionally substituted;one of X1and X2is N and the other is NR4, wherein R4is hydrogen, C1-6alkyl, or arylC1-6alkyl;or pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them.
REFERENCES:
patent: 4447431 (1984-05-01), Sallman
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 5717100 (1998-02-01), Selnick et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 2 306 108 (1994-04-01), None
patent: WO96/03387 (1996-02-01), None
patent: WO96/41645 (1996-12-01), None
patent: WO 97/12876 (1997-04-01), None
patent: WO 99/32436 (1997-04-01), None
patent: WO97/36587 (1997-10-01), None
patent: WO97/47618 (1997-12-01), None
patent: WO98/16227 (1998-04-01), None
patent: WO 99/03837 (1999-01-01), None
patent: WO99/21555 (1999-05-01), None
patent: WO 99/61437 (1999-12-01), None
patent: WO 01/37835 (2001-05-01), None
patent: WO 02/39954 (2002-05-01), None
Liverton, N.J et al: Design and Synthesis of Potent, Selective and Orally Bioavailable tetrasubstituted Imidazoles of p38 Mitogen Activated Protein Kinase. J. Med Chem 1999 42 2180-2190.
Lisnock, J et al: Molecular Basis for p38 Protein Kinase Inhibitor Specificity, BioChemistry, 1998, 37, 16573-16581.
Toledo L.M et al, The Structure-Based Design of ATP-site Directed Protein Kinase Inhibitors, Current Medicinal Chemistry 1999, 6, 775-805.
Stover D.R et al, Recent Advances in protein Kinase inhibition:Current molecular scaffolds used for inhibitor synthesis. Current Opinion in Drug Discovery and Development 1999 2(4) 274-285.
Salituro F.G, et al Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Disease, Current Medicinal Chemistry 1999, 6, 807-823.
Adams J.L. et al, Recent progress towards the idnetification of selective inhibitors of serine/theronine protein kinases, Current Opinion in Drug Discovery and Development 1999 2(2) 96-109.
Hall-Jackson C.A. et al, Effect of SB2030580 on the activity of c-Raf in vitro and and in vivo Oncogene (1999) 18, 2047-2054.
Boehm J. C. et al, New Inhibitors of p38 Kinase, Exp Opinion Ther Patents (2000) 10 (1).
Garcia-Echeverria C. et al, ATP Site Directed Competitive and Irreversible Inhibitors of Protein Kinase, Med Res Reviews 2000, 20(1), 28-57.
Wang Z et al, Structural basis of inhibitor selectivity in MAP Kinases, Structure Sep. 15, 1998, 6: 1117-1128.
Lackey K et al, The Discovery of Potent cRaf 1 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 223-226.
Adams. J.L et al, Pyrimidinylimidazole Inhibitors of CSBP/p38 Demonstrating Decreased inhibition of Hepatic Cytochrome p450 Enzymes, Bioorganic & Medical Chemistry Letters 8 (1998) 3111-3116.
Gallagher T.F et al, Regulation of Stress-Induced Cytokine Production by Pyridinylimidazole: Inhibition of CSBP Kinase; Bioorganic & Medical Chemistry vol. 5 No. 1 pp 49-64 1997.
Boehm J. C. et al, 1-Substituted 4-Aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-Lipoxygenase and cycloxygenase inhibitory potency, J. Med Chem 1996, 39 3929-3937.
Cuenda A. et al, SB203580 is a specific inhibitor of a MAP Kinase homologue which is stimulated by cellular stresses and interleukin-1, FEBS Letters 364 (1995) 229-233.
Lee J. C. et al, p 38 Mitogen-Activated Protein Kinase Inhibitors-Mechanisms and Therapeutic Potentials, Pharmacol Ther. vol. 82. Nos 2-3 pp 389-397, 1999.
Young P. R. et al, Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase bind in the ATP site, The Journal of Biological Chemistry vol. 272 No. 18 Issue of May 2 pp 12116-12121 1997.
Dumas J. et al, Discovery of a new class of p38 Kinase inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 2047-2050.
Dumas J, et al, 1-Phenyl-5-pyrazolyl Ureas Potent and Selective p38 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 2051-2054.
Revesz L, et al, SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10(2000) 1261-1264.
Laszlo S.E, et al, Pyrroles and other heterocycles as inhibitors of p38 Kinase, Bioorganic & Medical Chemistry Letters 8 (1998) 2689-2694.
Tong L. et, A highly specific inhibitor of human p38 MAP Kinase binds in the ATP pocket, Nature Structural Biology vol. 4 No. 4 Apr. 1997 p 311.
p38 Inhibitors based on pyridylurea and pyridylacetoamide templates, Exp Opin. Ther. Patents (2000) 10(7) 1151-1154.
Two Novel structural classes of p38 Kinase inhibitors, Exp Opin. Ther. Patents (1999) 9(4) 477-480.
Henry. J R., et al, Potent Inhibitors of the Map Kinase p38, Bioorganic & Medical Chemistry Letters 8 (1998) 3335-3340.
Henry. J. R., et al, p38 mitogen-activated protein kinase as a target for drug discovery, Drugs of the Future 1999, 24 (12) 1345-1354.
Lowinger, T.B. et al, Discovery of a novel class of potent BRaf kinase inhibitors: Strucutre activity relationships 335 Clinical Cancer Research vol. 6 Nov. 2000 (Supplement) Poster session 13 4533.
Eberwein D, et al, In vivo activity of a Raf kinase inhibitor in human tumor xenograft models, 406 Clinical Cancer Research vol. 6 Nov. 2000 (Supplement) Poster session 17 4547.
Claiborne C.F. et al, An efficient sythesis of Tertasubstituted Imidazoles from N-(2-Oxo)-amides, Tetrahedron Letters 39, (1998) 8939-3942.
Antolini M et al, Analogues of 4,5-bis(3,5-Dichlorophenyl)-2-trifluoromethyl-1H-Imidazole as Potential Antibacterial Agents. Bioorganic & Medical Chemistry Letters 9 (1999) 1023-1028.
Bilodeau M. T. et al, Solid-supported synthesis of Imidazoles: A Strategy for direct resin-attachment to the Imidazole Core. J. Org. Chem 1998 63. 2800-2801.
Astles P.C. et al, Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) Inhibitors.2.2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as Potent Inhibitors of ACAT, J. Med. Chem. 1996, 39, 1423.
Heimbrock, D.C. et al; Identification of Potent, Selective Inhibitors of Raf Protein Kinase, Amer. Assoc for Cancer Res New Orleans Apr. 1998.
Liverton, N.J. et al: Design and Synthesis of Potent, Selective and Orally Bioavailable tetrasubstituted Imidazoles of p38 Mitogen Activated Protein Kinase. J. Med Chem 1999 42 2180-2190.
Lisnock, J et al: Molecular Basis for p38 Protein Kinase Inhibitor Specificity, BioChemistry, 1998, 37, 16573-16581.
Toledo L., et al, The Structure-Based Design of ATP-site Directed Protein Kinase Inhibitors, Current Medicinal Chemistry 1999, 6, 775-805.
Stover D.R et al, Recent Advances in protein Kinase inhibition: Current molecular scaffolds used for inhibitor synthesis. Current Opinion in Drug Discovery and Development 1999 2(4) 274-285.
Salituro F.G, et al, Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Disease, Current Medicinal Chemistry 1999, 6, 807-823.
Adams J.L. et al, Recent progress towards the idnetification of selective inhibitors of serine/theronine protein kinases, Current Opinion in Drug Discovery and Development 1999 2(2) 96-109.
Hall-Jackson C.A. et al, Effect of SB203580 on the activity of c-Raf in vitro and in vivo Oncogene (1999) 18, 2047-2054.
Boehm J. C. et al, New inhibitors of p38 Kinase, Exp Opinion Ther Patents (2000) 10 (1).
Garcia-Echeverria C. et al, ATP Site Directed Competitive and Irreversible Inhibitors of Protein Kinase, Med Res Reviews 2000, 20(1),
Gaiba Alessandra
Takle Andrew Kenneth
Wilson David Matthew
Hsu Grace C.
Kinzig Charles M.
McCarthy Mary
Shameem Golam M M
SmithKline Beecham P.L.C.
LandOfFree
Imidazol-2-carboxamide derivatives as raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazol-2-carboxamide derivatives as raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazol-2-carboxamide derivatives as raf kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552660